Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q86SG6

UPID:
NEK8_HUMAN

ALTERNATIVE NAMES:
Never in mitosis A-related kinase 8; Nima-related protein kinase 12a

ALTERNATIVE UPACC:
Q86SG6; A6NIC5; Q14CL7; Q2M1S6; Q8NDH1

BACKGROUND:
The protein Serine/threonine-protein kinase Nek8 is essential for maintaining kidney tubule epithelial cell structure and plays a role in the Hippo signaling pathway, influencing organ size and tissue regeneration. Its alternative names include Never in mitosis A-related kinase 8 and Nima-related protein kinase 12a.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in diseases like Nephronophthisis 9 and Renal-hepatic-pancreatic dysplasia 2, targeting Nek8 offers a promising avenue for developing therapies aimed at mitigating these genetic disorders. Exploring Nek8's function could lead to groundbreaking therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.